Life Sciences Drug DevelopmentCambridge, Massachusetts
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company's discovery and development programs are built around its two patented transgenic mouse platforms (Harbour Mice) for human antibody therapeutic discovery. The company is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For additional information, please visit http://www.harbourbiomed.com.
About Harbour Mice
A fully owned subsidiary of Harbour BioMed, Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable biophysical properties. For additional information, please visit http://harbourantibodies.com.